ArticleScientific reports2021

Efficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell lines.

Keisuke Taniguchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.